Skip to main content
Top

ASH 2024 Rilzabrutinib safe and effective in ITP

MedNet.nl: The oral Bruton tyrosine kinase inhibitor rilzabrutinib demonstrated a strong therapeutic effect with a favorable safety profile in patients with immune thrombocytopenia (ITP) in the phase 3 LUNA 3 trial.

Are you up to date on targeted therapies for relapsed/refractory AML? 

Join Prof. Amer Zeidan and his expert guests to hear about innovations in molecular testing, emerging therapies, and IDH-targeted treatments, and get practical advice for improving your patient care.

Supported by: independent educational grant from Rigel

Find out more